Developer docs
API playgroundTry for free, no card

Search company profiles

NurrOn Pharmaceuticals

Full company profile

uuid0003h4n

Namestring
NurrOn Pharmaceuticals
Legal namestring
NurrOn Pharmaceuticals Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

NurrOn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Boston, Massachusetts, that develops disease-modifying therapies for Parkinson's disease and other Nurr1-related neurodegenerative disorders. The company's core technology is a proprietary Nurr1 Activator Platform targeting Nurr1, the nuclear receptor identified by co-founder Kwang Soo Kim as the master regulator of dopaminergic neuron development and maintenance. Its lead compound ATH-399A (also referenced as HL192) is designed with a dual mechanism: increasing transcriptional activation of dopaminergic-specific genes while enhancing transrepression of neurotoxic proinflammatory gene expression in microglia. The compound demonstrated significant improvement in behavioral deficits in 6-hydroxydopamine-lesioned rat and MPTP-lesioned mouse models of Parkinson's disease without detectable dyskinesia-like behavior.

NurrOn's pipeline extends beyond ATH-399A to additional investigational lead compounds for IND-enabling studies across Nurr1-related indications, with planned exploration of both monotherapy and combination approaches alongside existing Parkinson's drugs. The asset is being advanced through a March 2023 co-development agreement with South Korean biopharmaceutical firms HanAll Biopharma and Daewoong Pharmaceutical; together the partners initiated the first-in-human Phase 1 study in October 2023 and successfully completed it in November 2024. Additional non-dilutive funding was provided by the Michael J. Fox Foundation under its Translational Pipeline Program (2022 award; $1,700,000 disbursed in November 2024).

As a pre-revenue clinical-stage company with 11-50 employees, NurrOn has no commercialized products and therefore no product sales. The intended go-to-market path is licensing or partnership-based commercialization rather than building an internal commercial sales infrastructure. The company relies on scientific publications in peer-reviewed journals (Nature Communications, Nature Chemical Biology, Scientific Reports, Expert Opinion on Drug Discovery, PNAS) and press coverage following clinical milestones for visibility. Leadership comprises founder and Harvard professor Kwang Soo Kim, Ph.D.; CEO Deog Joong Kim, Ph.D. (formerly VP R&D at Rexahn Pharmaceuticals); Co-Founder George A. Lopez, MD (founder of ICU Medical); Acting CMO Thomas C. Wessel, MD, Ph.D. (prior CMO at Acorda, Flex Pharma, Asceneuron); and Chairman Tae Heum Jeong, D.Mgt. (founder of Adelphi Ventures). No institutional venture equity investors or parent company are disclosed.

Short descriptiontext

NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company developing disease-modifying Parkinson's disease therapies through its proprietary Nurr1 activator platform; lead compound ATH-399A successfully completed Phase 1 in November 2024 via a HanAll Biopharma and Daewoong Pharmaceutical co-development partnership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWoburn, United States
HQ citystring
Woburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Parkinson's therapeutics, neurodegenerative disease treatments, Nurr1 activator drugs, dopaminergic neuron therapy, CNS drug development
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Parkinson's Disease Therapeutics
No data
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company developing Nurr1-targeting small-molecule therapeutics for Parkinson's disease and other neurodegenerative disorders. Its lead asset is ATH-399A (HL192), a Nurr1 activator designed as a disease-modifying therapy to slow or prevent disease progression rather than merely treat symptoms, with successful completion of a first-in-human Phase 1 clinical study in November 2024.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Significant improvement in behavioral deficits in both 6-hydroxydopamine lesioned rat and MPTP-lesioned mouse models of PD without any detectable signs of dyskinesia-like behavior
+1 more record
Product overview1 text field

NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of disease-modifying therapies for Parkinson's disease and other Nurr1-related neurodegenerative disorders. The company's core product is ATH-399A (HL192), a lead Nurr1 activator compound that successfully completed first-in-human Phase 1 clinical trials in 2024. Built on a Nurr1 Activator Platform, the company is pursuing both monotherapy and combination approaches, with the goal of developing therapies that can work synergistically with existing PD drugs. The pipeline includes novel investigational lead compounds for IND-enabling studies targeting various neurodegenerative diseases.

Product and service1 record
1ATH-399A (also referred to as HL192)
CategoryParkinson's disease small-molecule therapeutic
Description

A small-molecule Nurr1 activator and the company's lead clinical-stage drug candidate, designed as a disease-modifying therapy to slow or prevent Parkinson's disease progression by targeting Nurr1, the master regulator for dopaminergic neuron development and maintenance, with potential for both monotherapy and combination use with existing Parkinson's drugs.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-29
Description

Co-development agreement to develop ATH-399A for Parkinson's disease. HanAll Biopharma is a South Korean biopharmaceutical company. The collaboration involves combining resources to develop NurrOn's lead compound ATH-399A, which aims to slow disease progression through targeting Nurr1 for neurodegenerative disorders.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-29
Description

Co-development agreement to develop ATH-399A for Parkinson's disease. Daewoong Pharmaceutical is a South Korean pharmaceutical company. The collaboration combines resources to develop NurrOn's lead compound ATH-399A targeting Nurr1 for Parkinson's disease and neurodegenerative disorders.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage CNS-focused biotech developing therapies for neurological disorders, with comparable development stage and CNS therapeutic focus.

TypeDirect peer
Description

Clinical-stage biotech focused on disease-modifying therapies for Parkinson's and other neurodegenerative diseases; Tae Heum Jeong, NurrOn's Chairman, also serves as CFO of Clene, indicating direct operational and strategic overlap.

TypeDirect peer
Description

Clinical-stage biotech developing disease-modifying therapies for Parkinson's and Alzheimer's diseases, addressing the same unmet need and competing for the same disease-modifying PD positioning as NurrOn.

TypeDirect peer
Description

Clinical-stage CNS-focused biotech (now Pfizer-owned) developing therapies for Parkinson's and other neurological disorders, with overlapping CNS drug development expertise and target patient population.

TypeDirect peer
Description

Clinical-stage CNS biotech developing therapeutics for neurodegenerative diseases; NurrOn's Acting CMO previously served as CMO at Asceneuron, and both target underserved CNS indications.

TypeDirect peer
Description

Clinical-stage CNS biotech developing novel therapeutics for neurological disorders, comparable in size, stage, and strategic positioning to NurrOn's CNS specialty focus.

TypeEmerging player
Description

Pharmaceutical company with marketed Parkinson's disease treatment (Opicapone/Dopicor) and active CNS pipeline, competing in the same PD therapeutic market with deeper resources.

TypeBroad incumbent
Description

Specialty CNS pharmaceutical company with Parkinson's disease franchise (Inbrija), comparable in therapeutic focus; NurrOn's Acting CMO previously served as CMO at Acorda.

TypeEmerging player
Description

Clinical-stage gene therapy company developing disease-modifying treatments for Parkinson's disease and other CNS disorders, addressing the same disease-modifying PD opportunity with a different modality.

TypeBroad incumbent
Description

Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, with broader CNS portfolio and substantially greater capital resources than NurrOn.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NurrOn Pharmaceuticals

Parkinson's Disease Therapeuticsnurronpharma.com

NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company developing disease-modifying Parkinson's disease therapies through its proprietary Nurr1 activator platform; lead compound ATH-399A successfully completed Phase 1 in November 2024 via a HanAll Biopharma and Daewoong Pharmaceutical co-development partnership.

What NurrOn Pharmaceuticals does

NurrOn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Boston, Massachusetts, that develops disease-modifying therapies for Parkinson's disease and other Nurr1-related neurodegenerative disorders. The company's core technology is a proprietary Nurr1 Activator Platform targeting Nurr1, the nuclear receptor identified by co-founder Kwang Soo Kim as the master regulator of dopaminergic neuron development and maintenance. Its lead compound ATH-399A (also referenced as HL192) is designed with a dual mechanism: increasing transcriptional activation of dopaminergic-specific genes while enhancing transrepression of neurotoxic proinflammatory gene expression in microglia. The compound demonstrated significant improvement in behavioral deficits in 6-hydroxydopamine-lesioned rat and MPTP-lesioned mouse models of Parkinson's disease without detectable dyskinesia-like behavior.

NurrOn's pipeline extends beyond ATH-399A to additional investigational lead compounds for IND-enabling studies across Nurr1-related indications, with planned exploration of both monotherapy and combination approaches alongside existing Parkinson's drugs. The asset is being advanced through a March 2023 co-development agreement with South Korean biopharmaceutical firms HanAll Biopharma and Daewoong Pharmaceutical; together the partners initiated the first-in-human Phase 1 study in October 2023 and successfully completed it in November 2024. Additional non-dilutive funding was provided by the Michael J. Fox Foundation under its Translational Pipeline Program (2022 award; $1,700,000 disbursed in November 2024).

As a pre-revenue clinical-stage company with 11-50 employees, NurrOn has no commercialized products and therefore no product sales. The intended go-to-market path is licensing or partnership-based commercialization rather than building an internal commercial sales infrastructure. The company relies on scientific publications in peer-reviewed journals (Nature Communications, Nature Chemical Biology, Scientific Reports, Expert Opinion on Drug Discovery, PNAS) and press coverage following clinical milestones for visibility. Leadership comprises founder and Harvard professor Kwang Soo Kim, Ph.D.; CEO Deog Joong Kim, Ph.D. (formerly VP R&D at Rexahn Pharmaceuticals); Co-Founder George A. Lopez, MD (founder of ICU Medical); Acting CMO Thomas C. Wessel, MD, Ph.D. (prior CMO at Acorda, Flex Pharma, Asceneuron); and Chairman Tae Heum Jeong, D.Mgt. (founder of Adelphi Ventures). No institutional venture equity investors or parent company are disclosed.

NurrOn Pharmaceuticals firmographics

Firmographics
Name
NurrOn Pharmaceuticals
Legal name
NurrOn Pharmaceuticals Inc.
Website
https://nurronpharma.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company developing disease-modifying Parkinson's disease therapies through its proprietary Nurr1 activator platform; lead compound ATH-399A successfully completed Phase 1 in November 2024 via a HanAll Biopharma and Daewoong Pharmaceutical co-development partnership.
Ownership category
akta.pro rank

NurrOn Pharmaceuticals industry classification

Industry
Product category
Parkinson's Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Parkinson's therapeutics
  • Neurodegenerative disease treatments
  • Nurr1 activator drugs
  • Dopaminergic neuron therapy
  • CNS drug development

Where NurrOn Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Woburn
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NurrOn Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Marketing channels2 records

NurrOn Pharmaceuticals product offering

Product offering

Core offering

NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company developing Nurr1-targeting small-molecule therapeutics for Parkinson's disease and other neurodegenerative disorders. Its lead asset is ATH-399A (HL192), a Nurr1 activator designed as a disease-modifying therapy to slow or prevent disease progression rather than merely treat symptoms, with successful completion of a first-in-human Phase 1 clinical study in November 2024.

Product overview

NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of disease-modifying therapies for Parkinson's disease and other Nurr1-related neurodegenerative disorders. The company's core product is ATH-399A (HL192), a lead Nurr1 activator compound that successfully completed first-in-human Phase 1 clinical trials in 2024. Built on a Nurr1 Activator Platform, the company is pursuing both monotherapy and combination approaches, with the goal of developing therapies that can work synergistically with existing PD drugs. The pipeline includes novel investigational lead compounds for IND-enabling studies targeting various neurodegenerative diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • ATH-399A (also referred to as HL192) A small-molecule Nurr1 activator and the company's lead clinical-stage drug candidate, designed as a disease-modifying therapy to slow or prevent Parkinson's disease progression by targeting Nurr1, the master regulator for dopaminergic neuron development and maintenance, with potential for both monotherapy and combination use with existing Parkinson's drugs.

Quantifiable outcome

  • Significant improvement in behavioral deficits in both 6-hydroxydopamine lesioned rat and MPTP-lesioned mouse models of PD without any detectable signs of dyskinesia-like behavior
  • +1 more outcomes

Companies that use NurrOn Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles2 records

NurrOn Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

NurrOn Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • HanAll BiopharmacoreStrategic or Co-development Partner · 29 March 2023Co-development agreement to develop ATH-399A for Parkinson's disease. HanAll Biopharma is a South Korean biopharmaceutical company. The collaboration involves combining resources to develop NurrOn's lead compound ATH-399A, which aims to slow disease progression through targeting Nurr1 for neurodegenerative disorders.
  • Daewoong PharmaceuticalcoreStrategic or Co-development Partner · 29 March 2023Co-development agreement to develop ATH-399A for Parkinson's disease. Daewoong Pharmaceutical is a South Korean pharmaceutical company. The collaboration combines resources to develop NurrOn's lead compound ATH-399A targeting Nurr1 for Parkinson's disease and neurodegenerative disorders.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

NurrOn Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Praxis Precision Medicines: Clinical-stage CNS-focused biotech developing therapies for neurological disorders, with comparable development stage and CNS therapeutic focus.
  • Clene Inc. Clinical-stage biotech focused on disease-modifying therapies for Parkinson's and other neurodegenerative diseases; Tae Heum Jeong, NurrOn's Chairman, also serves as CFO of Clene, indicating direct operational and strategic overlap.
  • Annovis Bio: Clinical-stage biotech developing disease-modifying therapies for Parkinson's and Alzheimer's diseases, addressing the same unmet need and competing for the same disease-modifying PD positioning as NurrOn.
  • Cerevel Therapeutics: Clinical-stage CNS-focused biotech (now Pfizer-owned) developing therapies for Parkinson's and other neurological disorders, with overlapping CNS drug development expertise and target patient population.
  • Asceneuron: Clinical-stage CNS biotech developing therapeutics for neurodegenerative diseases; NurrOn's Acting CMO previously served as CMO at Asceneuron, and both target underserved CNS indications.
  • Sage Therapeutics: Clinical-stage CNS biotech developing novel therapeutics for neurological disorders, comparable in size, stage, and strategic positioning to NurrOn's CNS specialty focus.

Emerging players

  • Bial - Portela & Cª: Pharmaceutical company with marketed Parkinson's disease treatment (Opicapone/Dopicor) and active CNS pipeline, competing in the same PD therapeutic market with deeper resources.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing disease-modifying treatments for Parkinson's disease and other CNS disorders, addressing the same disease-modifying PD opportunity with a different modality.

Broad incumbents

  • Acorda Therapeutics: Specialty CNS pharmaceutical company with Parkinson's disease franchise (Inbrija), comparable in therapeutic focus; NurrOn's Acting CMO previously served as CMO at Acorda.
  • Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, with broader CNS portfolio and substantially greater capital resources than NurrOn.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

NurrOn Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NurrOn Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

NurrOn Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NurrOn Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NurrOn Pharmaceuticals

What does NurrOn Pharmaceuticals do?

NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company developing Nurr1-targeting small-molecule therapeutics for Parkinson's disease and other neurodegenerative disorders. Its lead asset is ATH-399A (HL192), a Nurr1 activator designed as a disease-modifying therapy to slow or prevent disease progression rather than merely treat symptoms, with successful completion of a first-in-human Phase 1 clinical study in November 2024.

Is NurrOn Pharmaceuticals a public or private company?

NurrOn Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NurrOn Pharmaceuticals founded?

NurrOn Pharmaceuticals was founded in 2020. It employs 11 to 50 people.

Where is NurrOn Pharmaceuticals based?

NurrOn Pharmaceuticals is headquartered in Woburn, United States, in the North America region.

Who are NurrOn Pharmaceuticals's main competitors?

Direct peers on record are Praxis Precision Medicines, Clene Inc., Annovis Bio, Cerevel Therapeutics, Asceneuron and Sage Therapeutics. Emerging players are Bial - Portela & Cª and Voyager Therapeutics. Broad incumbents are Acorda Therapeutics and Denali Therapeutics.

Does NurrOn Pharmaceuticals have an API?

No public API is recorded for NurrOn Pharmaceuticals.

What industry is NurrOn Pharmaceuticals in?

NurrOn Pharmaceuticals's product category is Parkinson's Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireHanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's DiseaseHanAll Biopharma, Daewoong Pharmaceutical, and NurrOn Pharmaceuticals completed a Phase 1 study of HL192 (ATH-399A) for Parkinson's disease, enrolling 76 healthy participants. The study met safety and tolerability endpoints with no serious adverse events, and PK data support once-daily dosing. The companies plan to initiate the next clinical trial in Parkinson's patients.PR NewswireHanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation ForumHanAll Biopharma, Daewoong Pharmaceutical, and NurrOn Pharmaceuticals will present their ongoing Parkinson's disease program at the 7th Annual Sachs Associates Neuroscience Innovation Forum on January 7, 2024. The presentation highlights their Nurr1-focused program, including ATH-399A, a Nurr1 activator in Phase I. HanAll will also attend the J.P. Morgan Healthcare Conference from January 8-11.PR NewswireHanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of DirectorsNurrOn Pharmaceuticals appointed Dr. Almira Chabi to its board of directors, effective November 24, 2023. She brings experience as CMO and CDO at HanAll Biopharma and prior roles at Santen and Genentech. The appointment aligns with NurrOn's strategic goals for Parkinson's disease therapeutics.PR NewswireHanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192HanAll Biopharma, Daewoong Pharmaceutical, and NurrOn Pharmaceuticals initiated the first-in-human Phase 1 clinical trial of HL192 (ATH-399A) for Parkinson's disease, dosing the first healthy participant. The study assesses safety, tolerability, and pharmacokinetics of single and multiple doses, with initial results expected in the second half of 2024.KedglobalHanAll, Daewoong to develop Parkinson's treatment with US partnerHanAll Biopharma and Daewoong Pharmaceutical have entered a joint development agreement with US-based NurrOn Pharmaceuticals to advance treatments for neurodegenerative diseases, specifically focusing on the candidate drug ATH-399A for Parkinson's. The collaboration aims to accelerate R&D and prepare for Phase 1 clinical trials scheduled for this year, leveraging HanAll and Daewoong's previous Series A investment in NurrOn. This strategic partnership seeks to create synergistic effects in developing innovative therapies that protect dopaminergic neurons.PR NewswireHanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's DiseaseHanAll Biopharma and Daewoong Pharmaceutical entered a co-development agreement with NurrOn Pharmaceuticals to develop ATH-399A, a Nurr1-targeting therapy for Parkinson's disease. The Phase 1 clinical trial is expected to be initiated in 2023, with the partners also exploring the compound for other neurodegenerative disorders.BioSpaceHanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson’s DiseaseHanAll Biopharma and Daewoong Pharmaceutical have entered into a co-development agreement with NurrOn Pharmaceuticals to develop novel therapies for Parkinson's disease, specifically targeting Nurr1 with the lead compound ATH-399A. The Phase 1 clinical trial for this compound is expected to be initiated in 2023. This partnership aims to leverage the combined expertise of the involved companies to advance treatment options for neurodegenerative disorders.